BioCentury | Jan 10, 2020
Financial News

Jan. 9 Financial Quick Takes: Closes for two royalty funds; plus Apellis leads follow-on trio, Element, Omniome, Hinova, Emergex, Tscan, Calliditas

HealthCare Royalty, Sagard close royalty funds HealthCare Royalty Partners closed its HealthCare Royalty Partners IV fund at $1.8 billion. The firm also promoted four team members to managing director: Carlos Almodóvar, head of IR; Shin...
BioCentury | Nov 13, 2019
Product Development

Hua Phase III diabetes data make good on glucokinase but disappoint investors

Hua’s announcement that glucokinase activator dorzagliatin met its endpoints in a Phase III diabetes study marks a watershed moment for a target whose disease-modifying potential was long stymied by the limitations of previous compounds. Yet...
BioCentury | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

New biological insights and increased recognition from FDA are transforming osteoarthritis from a testing ground for new pain therapies into its own high-priority indication. At least two mechanisms with disease-modifying potential for osteoarthritis (OA) have...
BioCentury | Jun 3, 2019
Product Development

There are opportunities to eradicate opioid misuse: Investors and innovators should seize them

Eradicating opioid misuse and addiction will take an integrated, holistic approach involving prevention, treatment, and recovery. Crucially, it will also take the help of investors and innovators in biotechnology who understand the challenges and opportunities...
BioCentury | Dec 5, 2018
Financial News

Burrill gets 30 months in prison for fraud

A federal court sentenced G. Steven Burrill to 30 months in prison for tax evasion and defrauding investors in a scheme to siphon money from the Burrill Life Sciences Capital Fund III. The U.S. District...
BioCentury | Nov 3, 2018
Product Development

New partners for NASH

Pharmas are loading up their NASH portfolios expecting that addressing the full disease spectrum will require combinations, though the field lacks the tools to sort the different mechanisms on offer strategically. Meanwhile, at least three...
BioCentury | Nov 2, 2018
Clinical News

Cirius NASH candidate improves liver enzymes in Phase IIb

Cirius Therapeutics Inc. (Kalamazoo, Mich.) reported interim data from 328 evaluable patients with biopsy-proven non-alcoholic steatohepatitis (NASH) with fibrosis and no cirrhosis in the Phase IIb EMMINENCE trial showing that MSDC-0602K reduced liver enzymes from...
BioCentury | Sep 28, 2018
Politics & Policy

IRS considering biotech-friendly spinout rule

The Internal Revenue Service announced it intends to revisit rules that could make it easier for biotechs to spin out assets. In a statement, the IRS Office of the Chief Counsel announced a study and...
BioCentury | Jul 13, 2018
Clinical News

Ironwood reports Phase IIb data of praliciguat to treat diabetes with hypertension

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) reported data from 26 diabetic patients with hypertension in a Phase IIa study showing that compared with placebo praliciguat (IW-1973) reduced blood pressure (6.3 vs. 1.5 mmHg), fasting glucose levels (32.5...
BioCentury | Jul 10, 2018
Distillery Therapeutics

Endocrine/Metabolic

...In white adipose tissue from the model, FST knockdown plus insulin increased phosphorylation of insulin receptor substrate 1 (IRS1...
...doi:10.1038/s41591-018-0048-0 CONTACT: Morris White, Harvard Medical School, Boston, Mass. email: morris.white@childrens.harvard.edu Allison Johnson Harvard Medical School Follistatin (FST) Insulin receptor substrate 1 (IRS1) Protein...
Items per page:
1 - 10 of 502